Mass Tort brief
Teva's U.S. Legal Fronts
Trial pool selections in Paragard MDL and a $400M competitor settlement leave Israeli generic giant Teva exposed across major product liability and antitrust suits.
Mass Tort
Competitor antitrust settlements strip Teva of co-defendant cover — raising financial risks for the Israeli generic maker as state prosecutors turn their full focus toward Tel Aviv.
BackgroundState prosecutors sued major generic manufacturers for allegedly coordinating price increases and allocating market share across hundreds of medication formulations. As co-defendants settle, legal pressure and financial exposure concentrate heavily on non-settling generic producers.
- The $400M agreement resolves claims brought by a bipartisan coalition of state legal authorities against Novartis unit Sandoz, leaving Teva isolated.
- Teva remains locked in federal litigation covering dozens of generic product lines, facing potential treble damages if state cases proceed to trial.
- Peer corporate settlements set higher baseline financial valuations, narrowing Teva's room to negotiate smaller multi-state payouts without facing heavy litigation.
Mass Tort
Equal bellwether case allocation isolates Teva's legacy manufacturing liability — setting up September jury verdicts that will determine the pharmaceutical giant's ultimate settlement exposure.
BackgroundTeva Pharmaceuticals originally manufactured and distributed the Paragard birth control device before selling the product line to CooperSurgical in 2017. Thousands of plaintiffs allege design defects cause the copper device to break during removal, requiring surgical intervention.
- District Judge Leigh Martin May selected eight Teva-era and eight CooperSurgical-era cases to establish representative trial outcomes for thousands of pending lawsuits.
- The upcoming Robere v. Teva trial begins on September 28 following a defense verdict in February, marking the next critical test of corporate liability.
- Jury verdicts in these initial bellwether cases will establish financial benchmarks for eventual global settlement negotiations across the multidistrict litigation.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.